Inhibrx Biosciences is the lead sponsor of 4 current clinical trials in our USA, UK, Ireland and China registers. 2 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Carboplatin, INBRX-109 and Pembrolizumab. The most-studied condition is Conventional Chondrosarcoma.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT03715933 · ClinicalTrials.gov ↗ · Ewing Sarcoma, Colorectal Adenocarcinoma
|
Phase 1 | Recruiting | 2018-10 | UK, USA |
|
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766 · ClinicalTrials.gov ↗ · Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer
|
Phase 1/2 | Recruiting | 2019-12 | USA |
|
Study of INBRX-109 in Conventional Chondrosarcoma
NCT04950075 · ClinicalTrials.gov ↗ · Conventional Chondrosarcoma
Drug: INBRX-109 |
Phase 2 | Active, closed | 2021-09 | Ireland, UK, USA |
|
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
NCT06295731 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma (HNSCC)
Drug: Pembrolizumab |
Phase 2/3 | Active, closed | 2024-05 | UK, USA, China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 4 | 2 |
| Clinical trials in UK | 3 | 1 |
| Clinical trials in Ireland | 1 | 0 |
| Clinical trials in China | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Inhibrx Biosciences is the lead sponsor of 4 current trials on ClinicalTrials.gov in our USA, UK, Ireland and China registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of its 4 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 13 drugs and biologicals as interventions. The most frequent are Carboplatin (2), INBRX-109 (2), Pembrolizumab (2), Pemetrexed (2) and Bevacizumab (1). The number in brackets is how many of its trials name each drug.
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.